A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants
A Double-Blind, Randomized, Placebo-Controlled, Combined Single Ascending Dose and Multiple Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AB102 in Healthy Participants
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Medical Director
- Telefonnummer: +1-510-462-3330
- E-mail: ClinicalTrialInquiry@arcusbio.com
Studiesteder
-
-
-
Groningen, Holland
- Rekruttering
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Understands the study procedures in the Informed Consent Form and is willing and able to comply with the protocol.
- BMI: 19.0 to 30.0 kg/m2, inclusive, at screening.
- All prescribed medication must have been stopped at least 30 days prior to admission to the clinical site. An exception is made for hormonal contraceptives that may be used throughout the study.
- Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG, vital signs, and complete neurological examination, as judged by the Investigator.
- Participants must follow protocol-specified contraception guidance.
Exclusion Criteria:
- Have a history of relevant atopy, drug hypersensitivity and/or food allergies.
- Using tobacco products within 3 months prior to the screening.
- Have a significant infection or known inflammatory process on screening or admission.
- Have received any vaccination within 14 days of admission date for non-live vaccines or 28 days of admission date for live attenuated vaccines.
- History of alcohol abuse or drug addiction in the last 2 years (including soft drugs like cannabis products).
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: SAD Part
Escalating single oral doses of AB102 will be given to participants
|
Administered orally as specified in the treatment arm
|
|
Eksperimentel: SAD Part Placebo
Escalating single oral doses of placebo will be given to participants
|
Administered orally as specified in the treatment arm
|
|
Placebo komparator: MAD Part
Escalating multiple oral doses of AB102 will be given to participants
|
Administered orally as specified in the treatment arm
|
|
Placebo komparator: MAD Part Placebo
Escalating multiple oral doses of placebo will be given to participants
|
Administered orally as specified in the treatment arm
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of participants experiencing Adverse Events (AEs)
Tidsramme: Up to 49 days
|
Up to 49 days
|
|
Maximum observed plasma concentration (Cmax) for SAD and MAD Parts
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Time to attain maximum observed plasma concentration (tmax) for SAD and MAD Parts
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Terminal elimination half-life (t1/2) for SAD Part
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve from time 0 to last sample (AUClast) for SAD and MAD Parts
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24h) for SAD Part
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for SAD Part
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Area under the plasma concentration-time curve over a dosing interval (AUC0-tau) for MAD Part
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Accumulation ratio (Racc(Cmax))for MAD Part
Tidsramme: Up to 28 days
|
Up to 28 days
|
|
Accumulation ratio(Racc(AUCtau)) for MAD Part
Tidsramme: Up to 28 days
|
Up to 28 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Medical Director, Arcus Biosciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ARC-102-101
- 2026-526279-52-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .